Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of HZ/su vaccine in older adults (ZOSTER-049 follow-up in ZOSTER-101)
jRCT2071220038Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by GSK. Primary endpoint: Number of participants in LTFU and Control groups with confirmed HZ cases (primary). Started Aug 2022; status: active, not recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on jRCT2071220038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220038.